Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
20.98 (1y: +112%)
Market Cap 2.13 B P/E(ttm)
Enterprise Value 1.95 B P/B 11.70
ISIS- NAS (USA)
Isis Pharmaceuticals
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$20.98
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt 4.521
ISIS's Cash to Debt is ranked lower than
61% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. ISIS: 4.521 )
ISIS' s 10-Year Cash to Debt Range
Min: 0.42   Max: 36.47
Current: 4.52
0.42
36.47
Equity to Asset 0.301
ISIS's Equity to Asset is ranked lower than
70% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ISIS: 0.301 )
ISIS' s 10-Year Equity to Asset Range
Min: -0.56   Max: 0.42
Current: 0.3
-0.56
0.42
F-Score: 4
Z-Score: 1.96
M-Score: -3.3
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -67.50
ISIS's Operating margin (%) is ranked lower than
56% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. ISIS: -67.50 )
ISIS' s 10-Year Operating margin (%) Range
Min: -277.7   Max: -12.2
Current: -67.5
-277.7
-12.2
Net-margin (%) -64.2
ISIS's Net-margin (%) is ranked lower than
56% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. ISIS: -64.2 )
ISIS' s 10-Year Net-margin (%) Range
Min: -334.3   Max: 127.5
Current: -64.2
-334.3
127.5
ROE (%) -35.8
ISIS's ROE (%) is ranked lower than
67% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ISIS: -35.8 )
ISIS' s 10-Year ROE (%) Range
Min: -7400   Max: 53.2
Current: -35.8
-7400
53.2
ROA (%) -12
ISIS's ROA (%) is ranked lower than
52% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. ISIS: -12 )
ISIS' s 10-Year ROA (%) Range
Min: -68.4   Max: 23.6
Current: -12
-68.4
23.6
ROC (Joel Greenblatt) (%) -97.60
ISIS's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ISIS: -97.60 )
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2835.9   Max: -97.6
Current: -97.6
-2835.9
-97.6
Revenue Growth (%) -5
ISIS's Revenue Growth (%) is ranked lower than
72% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ISIS: -5 )
ISIS' s 10-Year Revenue Growth (%) Range
Min: -22.2   Max: 39.2
Current: -5
-22.2
39.2
EBITDA Growth (%) 35.9
ISIS's EBITDA Growth (%) is ranked higher than
97% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ISIS: 35.9 )
ISIS' s 10-Year EBITDA Growth (%) Range
Min: -44.9   Max: 71.1
Current: 35.9
-44.9
71.1
ยป ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ISIS Guru Trades in Q2 2012

Columbia Wanger 5,083,000 sh (unchged)
Murray Stahl 29,000 sh (unchged)
Jim Simons 171,800 sh (-31.39%)
» More
Q3 2012

ISIS Guru Trades in Q3 2012

Murray Stahl 29,000 sh (unchged)
Columbia Wanger 5,083,000 sh (unchged)
Jim Simons 47,900 sh (-72.12%)
» More
Q4 2012

ISIS Guru Trades in Q4 2012

Murray Stahl 29,000 sh (unchged)
Columbia Wanger Sold Out
Jim Simons Sold Out
» More
Q1 2013

ISIS Guru Trades in Q1 2013

Steven Cohen 19,433 sh (New)
Louis Moore Bacon 125,000 sh (New)
Murray Stahl 17,000 sh (-41.38%)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-06-30 Sold Out $8.54 - $9.38 $ 20.98135%0
George Soros 2011-03-31 New Buy$8.57 - $10.35 $ 20.98128%22300
Jean-Marie Eveillard 2010-12-31 Sold Out 0.01%$8.05 - $10.51 $ 20.98121%0
Jean-Marie Eveillard 2010-09-30 New Buy0.01%$7.775 - $10.07 $ 20.98140%100000
George Soros 2010-09-30 Sold Out $7.775 - $10.07 $ 20.98140%0
George Soros 2010-06-30 New Buy$8.84 - $11.13 $ 20.98111%16100
Jean-Marie Eveillard 2010-03-31 Sold Out 0.01%$8.66 - $11.76 $ 20.98104%0
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 11.70
ISIS's P/B is ranked lower than
83% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ISIS: 11.70 )
ISIS' s 10-Year P/B Range
Min: 1.24   Max: 1710
Current: 11.7
1.24
1710
P/S 17.33
ISIS's P/S is ranked lower than
68% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. ISIS: 17.33 )
ISIS' s 10-Year P/S Range
Min: 2.16   Max: 46.93
Current: 17.33
2.16
46.93
EV-to-EBIT 200
ISIS's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. ISIS: 200 )
ISIS' s 10-Year EV-to-EBIT Range
Min: 108.9   Max: 2448.3
Current: 200
108.9
2448.3

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 190.7
ISIS's Price/Net Cash is ranked lower than
99% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. ISIS: 190.7 )
ISIS' s 10-Year Price/Net Cash Range
Min: 5.2   Max: 139
Current: 190.7
5.2
139
Price/Net Current Asset Value 524.5
ISIS's Price/Net Current Asset Value is ranked lower than
94% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. ISIS: 524.5 )
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 21.3   Max: 370.7
Current: 524.5
21.3
370.7
Price/Tangible Book 13
ISIS's Price/Tangible Book is ranked lower than
78% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. ISIS: 13 )
ISIS' s 10-Year Price/Tangible Book Range
Min: 3.4   Max: 39.4
Current: 13
3.4
39.4
Price/DCF (Projected) 524.5
ISIS's Price/DCF (Projected) is ranked lower than
100% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. ISIS: 524.5 )
ISIS' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 524.5
Price/Median PS Value 1.8
ISIS's Price/Median PS Value is ranked lower than
76% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ISIS: 1.8 )
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 3.6
Current: 1.8
0.5
3.6
Forward Rate of Return (Yacktman) -0.55
ISIS's Forward Rate of Return (Yacktman) is ranked lower than
62% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ISIS: -0.55 )
ISIS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -51.9   Max: -1.1
Current: -0.55
-51.9
-1.1

Business Description

Isis Pharmaceuticals was incorporated in California on January 10, 1989, and reorganized as a Delaware corporation in April 1991. Isis Pharmaceuticals is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. Its flagship product, KYNAMRO (formerly mipomersen), is moving closer to the market for patients with severe forms of familial hypercholesterolemia, or FH, at high cardiovascular risk, who cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. In addition to KYNAMRO, many of the other drugs in its pipeline are demonstrating encouraging clinical activity in a variety of diseases. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ISI.Germany
ยป More Articles for ISIS

Headlines

Articles On GuruFocus.com
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 
Weekly Guru Bargains Highlights: MetroPCS Communications Inc, Isis Pharmaceuticals Inc, Leap Wireles Jan 24 2010 
Weekly Guru Bargains Highlights: Isis Pharmaceuticals Inc, MetroPCS Communications Inc, American Int Jan 09 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial